Adagene Inc ADR Dossier - Source-backed chat

Adagene Inc ADR

ADAGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.72

Intrinsic Value $2.06median of 2 methodsbased on filings through 31 Dec 2025

Market Price $3.20Price as of 30 Sep 2026

OvervaluedIntrinsic value is 36% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $214.9M

Enterprise Value $142.2M

Shares Outstanding 59M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Adagene Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and computational biology to design next-generation antibody-based cancer immunotherapies. The investment thesis centers on its proprietary SAFEbody® precision masking technology, which conditionally activates antibodies in the tumor microenvironment (TME) to dramatically expand the therapeutic index. Its lead asset, muzastotug (ADG126), is a masked anti-CTLA-4 antibody that has demonstrated a highly differentiated safety profile and potent, dose-dependent efficacy in cold tumors like microsatellite stable colorectal cancer (MSS CRC). By overcoming the severe systemic toxicities that limit first-generation CTLA-4 inhibitors (such as ipilimumab), muzastotug can be dosed up to 10-20x higher, enabling sustained intratumoral Treg depletion and effector T-cell priming. Backed by a solid cash runway extending into early 2028 and high-value global partnerships with Sanofi, Roche, and Exelixis, Adagene represents a high-upside opportunity in the oncology space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$10.74

High · most bullish analyst$17.45

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

Muzastotug encounters unexpected late-stage safety signals or fails to show a statistically significant efficacy advantage over standard of care in randomized cohorts. Partner programs face delays or terminations, accelerating cash burn and forcing highly dilutive equity financing.

Base CaseCentral scenario

$8.0050%

Muzastotug continues to show consistent safety and competitive efficacy in its ongoing randomized Phase 2 dose-optimization trials. The cash runway remains secure into 2028, supported by ATM offerings and partner milestones. Wall Street consensus maintains a positive outlook with steady progression toward registrational trials.

Bull CaseUpside scenario

$10.0030%

Muzastotug (ADG126) delivers outstanding Phase 2 data in MSS CRC, establishing itself as a best-in-class next-generation CTLA-4 backbone therapy. Sanofi and Roche expand their partnerships, triggering substantial milestone payments. The SAFEbody platform is validated across multiple T-cell engager and ADC programs, leading to a lucrative licensing or acquisition offer from a major pharmaceutical peer.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary SAFEbody® technology solves the historical toxicity-efficacy trade-off of CTLA-4 and CD137 pathways through highly efficient tumor-specific masking.
Muzastotug (ADG126) has demonstrated a 29% confirmed ORR in combined 20 mg/kg cohorts and a mature mOS of 19.4 months in 10 mg/kg cohorts for late-line MSS CRC, significantly outperforming historical standard of care.
Strong validation from global pharmaceutical leaders, including Roche (sponsoring a triple combination trial in HCC) and Sanofi (strategic investment and co-development).
Robust financial position with $74.5 million in cash (as of Dec 31, 2025) and ATM proceeds extending the operational runway into early 2028.

Key Investment Risks

High clinical development risk inherent to early/mid-stage oncology assets, where historical failure rates are high.
Intense competition in the next-generation CTLA-4 and immunotherapy space from both established biopharma giants and emerging biotech peers.
Dependence on external partners (Roche, Sanofi, Exelixis) for clinical execution and platform validation.

Thesis Invalidation Triggers

Failure of muzastotug to meet primary efficacy endpoints or show dose-dependent survival benefits in randomized Phase 2 trials.
Occurrence of severe, unexpected Grade 4/5 treatment-related adverse events (TRAEs) that compromise the safety thesis of the SAFEbody platform.
Termination of key strategic collaborations by Sanofi or Roche.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.